Monte Rosa Therapeutics (GLUE) Other Non-Current Liabilities (2020)

Monte Rosa Therapeutics' (GLUE) quarterly Other Non-Current Liabilities came in at $67.8 million in Q4 2020.

Monte Rosa Therapeutics (GLUE) Other Non-Current Liabilities (2020) Analysis & Trends

Monte Rosa Therapeutics' Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $67.8 million for Q4 2020.

On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $67.8 million in Q4 2020; TTM through Dec 2020 was $67.8 million, a N/A change from a year earlier, with the FY2020 full-year figure at $67.8 million, changed N/A from the prior year.
Other Non-Current Liabilities was little changed at $67.8 million in Q4 2020 per GLUE's latest filing.
Across five years, Other Non-Current Liabilities topped out at $67.8 million in Q4 2020 and bottomed at $67.8 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Monte Rosa Therapeutics	2.30 Bn	1.62 Bn	-

Download Data

Date	Value
Dec 31, 2020	67.76 Mn